{"id":65725,"name":"DENALI THERAPEUTICS","slug":"denali-therapeutics","state":"CA","country":"United States of America","description":"Biopharmaceutical Company","totalSpending":342500,"filings":6,"yearlySpending":[{"year":2025,"income":342500}],"issues":[{"code":"HCR","display":"Health Issues"}],"firms":["MANATT, PHELPS, AND PHILLIPS"],"lobbyists":["RACHEL SHER","HEIDE BAJNRAUH","KENDALL HUSSEY"],"govEntities":[],"sampleDescriptions":["Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Medicaid policies that impact access to innovative treatments for pediatric rare diseases; rare disease drug development","Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Medicaid policies that impact access to innovative treatments for pediatric rare diseases; rare disease drug development","Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Medicaid policies that impact access to innovative treatments for pediatric rare diseases; rare disease drug development","Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Medicaid policies that impact access to innovative treatments for pediatric rare diseases; rare disease drug development","Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Rare disease drug development"]}